Provectus Pharmaceuticals Inc. is quickly gaining a reputation as an up-and-coming development-stage oncology and dermatology biopharmaceutical company. Helping to enhance this reputation and its position in the marketplace, Provectus announced the addition of Mount Sinai School of Medicine as the second and final site for its expanded Phase 2 clinical trial of the company’s lead dermatology agent PH-10 for psoriasis. Jason Elmer, M.D., who served as the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis of which patent enrollment was completed in June, will also serve as the principal investigator of this trial.

Commenting on the value of Dr. Elmer’s work on this project, Provectus CEO Craig Dees, Ph.D. stated, “Dr. Emer’s work with PH-10 for atopic dermatitis, his involvement in the ongoing research of the product as a dermatological therapy, and Mount Sinai School of Medicine’s outstanding reputation in dermatological research make this

Solei Systems Incorporated is an industry leader in the field of tanning and LED products. As of May 2, 2008 the company began trading on the Pink Sheets exchange, and CEO Paul Spivak anticipates that, within the next few months, the company will transition onto a senior exchange. The company consists of three divisions: Intelligent Tanning Systems (ITS), Light Therapy Systems (LTS) and BioScience Systems. All three of these divisions manufacture their own equipment in-house, which greatly reduces costs and increases efficiency.

The Intelligent Tanning Systems division is focused on sunless tanning machines and equipment to meet the needs of today’s marketplace. The tanning machines and equipment offered through ITS are ultra-violet (UV) free and offer an affordable option for both retail and residential customers. ITS has also developed a patent pending, state-of-the-art LED tanning technology that is the only one of its kind, and has